# Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

> **NCT00840853** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 68 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Non Hodgkin's Lymphoma

## Interventions

- **GENETIC:** CD19CAR/virus specific T cells
- **DRUG:** Benadryl and Tylenol

## Key facts

- **NCT ID:** NCT00840853
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-04
- **Primary completion:** 2016-04
- **Final completion:** 2031-04
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-07-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00840853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00840853, "Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00840853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*